Klin Farmakol Farm. 2008;22(3):113-115
Glycylcyclines - a new class of antibiotics
- Ústav farmakologie LF UP a FN Olomouc
Glycylcyclines are a new class of antibiotics derived from minocycline. These tetracycline analogues are specifically designed to overcome mechanisms of tetracycline resistance, namely resistance mediated by acquired efflux pumps and/or ribosomal protection. Presently, tigecycline is the only glycylcycline antibiotic for clinical use. Tigecycline is a broad-spectrum bacteriostatic parenteral agent active against many Gram-positive bacteria, Gram-negative bacteria and anaerobes, including activity against multidrugresistant strains. It has no activity against Pseudomonas spp. or Proteus spp. It is given by slow intravenous infusion – single dose of 100 mg is given first, followed by 50 mg every twelve hours. The most common side effects of tigecycline are diarrhea, nausea and vomiting. The drug is licenced for the treatment of complicated skin and soft tissue as well as intra-abdominal infections.
Keywords: Key words: glycylcyclines, tigecycline, antibiotics.
Published: January 1, 2009 Show citation
References
- Frampton JE, Curran MP. Tigecycline. Drugs 2005; 65(18): 2623-2635.
Go to original source... 
Go to PubMed... - Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006; 6: 486-490. Go to original source... Go to PubMed...
- Noskin GA. Tigecycline: A new Glycylcycline for Treatment of Serious Infections. Clin Infect Dis 2005; 41: S303-314 Go to original source... Go to PubMed...
- Levy SB. Antibiotický paradox. Jak se nesprávným používáním ruší jejich léčebná moc. Nakladatelství Academia, Středisko společných činností AV ČR, Praha 2007.
- Garrison MW, Neumiller JJ, Setter SM. Tigecycline: An Investigational Glycylcycline Antimicrobial with Activity Against Resistant Gram-Positive Organisms. Clin Ther 2005; 27(21): 12-22. Go to original source... Go to PubMed...
- Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract, December 2006; 60 (12): 1662-1672. Go to original source... Go to PubMed...
- Fraise AP. Tigecycline: The answer to beta-lactam and fluoroquinolone resistance? J Infect 2006; 53: 293-300. Go to original source... Go to PubMed...
- Wilcox MH. Tigecycline and the Need for a New Broad-Spectrum Antibiotic Class. Surg Infect (Larchmt) 2006; 7(1): 69-80. Go to original source... Go to PubMed...
- Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline. Clin Infect Dis 2005; 41: S333-340. Go to original source... Go to PubMed...
- Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470-480. Go to original source... Go to PubMed...
- Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tiegecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveilance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-227. Go to original source... Go to PubMed...
- Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, et al. Acinetobacter baumanii bloodstream infection while receving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59(1):128-131. Go to original source... Go to PubMed...
- Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25: 185-192. Go to original source... Go to PubMed...
- Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother. 2007; 41(6): 965-972. Go to original source... Go to PubMed...
- Souhrn údajů o přípravku SPC Tygacil, Wyeth.
- Stein GE, Craig WA. Tigecycline: A Critical Analysis. Clin Infect Dis 2006; 43: 518-524. Go to original source... Go to PubMed...
- Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Abdominal Infections: Analysis of Pooled Clinical Trial Data. Clin Infect Dis 2005; 41: S354-367. Go to original source... Go to PubMed...
- Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin-Structure Infections: Results of 2 Double-Blind Phase 3 Comparison Studies with Vancomycin-Aztreonam. Clin Infect Dis 2005; 41: S341-353. Go to original source... Go to PubMed...
- Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumanii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55(1): 49-57. Go to original source... Go to PubMed...
- Stein GE. Safety of Newer Parenteral Antibiotics. Clin Infect Dis 2005; 41: S293-302. Go to original source... Go to PubMed...